INTRODUCTIONPediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs).METHODSIn a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped.RESULTSS. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1-4.3 years] vs. median 5.6 years [IQR 3.8-8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1.CONCLUSIONFollowing the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3.

01 Feb 1978·The Bulletin of Tokyo Dental College

Phospholipid-induced agglutination of plaque bacteria.

Article

Author: Takazoe, I ; Takeshima, H ; Matsukubo, T ; Katow, T

Nigerian medical journal : journal of the Nigeria Medical Association

Timeliness of Vaccination among Children Attending Immunization Clinic at a Tertiary Hospital in South-East Nigeria.

Article

Author: Umeokonkwo, Adanna Anthonia ; Ezeonu, Thecla Chinonyelum ; Umeokonkwo, Chukwuma David ; Agu, Adaoha Pearl

BackgroundTimely vaccination of children is one of the most cost-effective interventions that ensure childhood survival. We determined the proportion of children who received timely vaccination and examined the factors associated with timely receipt of Bacillus Calmette Guerin (BCG) and third dose of pentavalent vaccine (Penta 3).MethodologyWe conducted a cross-sectional survey among 599 caregivers-infant pair aged less than 24months, attending the immunization clinic of a tertiary hospital in Nigeria, selected using systematic sampling methods. Using a structured questionnaire, we access the proportion of children who received timely vaccination, the relationship between the timely receipt of BCG, Penta 3 vaccine and infant/caregiver characteristics was examined using chi-square and multiple logistic regression at a 5% level of significance.ResultsThe mean age of the respondents was 30.1±5.0 years. The majority (73.8%) had attained tertiary education, lived in an urban setting (90.9%), had received antenatal care during pregnancy (99.3%) and was delivered in a hospital (97.0%). About half of the children (52.9%) were male. About 18% of the caregivers reported missing scheduled immunization visits, due to forgetfulness (18%), child illness (14%) and being busy (5%). About 88% (482) of the children got their BCG vaccines on time, 91.1% got timely OPV0, however, only 29.5% of the newborns got HBV0 within 24 hours of birth. Only 65.7% and 65.0% received the timely measles-containing vaccine and yellow fever vaccine. None of the factors examined predicted timely receipt of BCG and Penta 3 vaccines.ConclusionInterventions that remind caregivers about the immunization schedules, could improve timely vaccination.

100 Deals associated with Rabies 3 dose vaccine (CPL Biologicals )

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rabies	Phase 3	-	CPL Biologicals Pvt Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rabies 3 dose vaccine (CPL Biologicals )

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation